PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes

Autor: Masayuki Takagi, Tomoyuki Miyazawa, Masahiro Hoshikawa, Haruhiko Nakamura, Koji Kojima, Hisashi Saji, Hideki Marushima
Rok vydání: 2019
Předmět:
Male
Pulmonary and Respiratory Medicine
programmed death-ligand 1
Pathology
medicine.medical_specialty
Lung Neoplasms
Time Factors
Lymphovascular invasion
Clone (cell biology)
Adenocarcinoma of Lung
030204 cardiovascular system & hematology
B7-H1 Antigen
subtype
03 medical and health sciences
0302 clinical medicine
Risk Factors
Carcinoma
Non-Small-Cell Lung
Biomarkers
Tumor
Carcinoma
Humans
Medicine
early adenocarcinoma
Pneumonectomy
Lung cancer
Aged
Neoplasm Staging
Aged
80 and over
Univariate analysis
business.industry
Gastroenterology
General Medicine
Middle Aged
medicine.disease
Immunohistochemistry
Progression-Free Survival
lung cancer
Treatment Outcome
030228 respiratory system
programmed cell death 1
Tumor progression
Disease Progression
Adenocarcinoma
Female
Original Article
Surgery
Neoplasm Recurrence
Local
Cardiology and Cardiovascular Medicine
business
Zdroj: Annals of Thoracic and Cardiovascular Surgery
ISSN: 2186-1005
1341-1098
DOI: 10.5761/atcs.oa.18-00163
Popis: Purpose: Knowledge regarding programmed death-ligand 1 (PD-L1) expression in lung cancer is limited. We aim to clarify PD-L1-positive expression in non-small-cell lung cancer (NSCLC), including adenocarcinoma subtypes. Methods: In all, 90 NSCLC specimens containing various adenocarcinoma subtypes, in addition to squamous cell carcinoma and large-cell carcinoma were selected. PD-L1 was immunohistochemically stained by murine monoclonal antibody clone 22C3. Results: When PD-L1-positive expression was defined by tumor proportion score (TPS) ≥1%, the positive cases were 0/11 in adenocarcinoma in situ, 0/12 in minimally invasive adenocarcinoma, 1/10 in lepidic predominant adenocarcinoma, 1/13 in papillary predominant adenocarcinoma, 8/14 in acinar predominant adenocarcinoma, 6/11 in solid predominant adenocarcinoma, 0/3 in micropapillary predominant adenocarcinoma, 0/4 in invasive mucinous adenocarcinoma, 4/9 in squamous cell carcinoma, and 2/3 in large-cell carcinoma. PD-L1 positivity was higher in males, smokers, advanced pathologic stages, positive vessel invasion, and positive lymphatic invasion. Postoperative survival analysis revealed that PD-L1-positive expression was a significantly worse prognostic factor in univariate analysis for recurrence-free survival (RFS). Conclusion: PD-L1-positive tumors were frequent in acinar predominant adenocarcinoma and solid predominant adenocarcinoma than other adenocarcinoma subtypes. PD-L1 expression seemed to increase according to pathologic tumor progression, suggesting a worse postoperative prognosis in NSCLC patients.
Databáze: OpenAIRE
Externí odkaz: